Marelin (Tablets) Instructions for Use
Marketing Authorization Holder
Vifitech, CJSC (Russia)
ATC Code
G04B (Drugs for the treatment of urological diseases)
Dosage Form
| Marelin | Coated tablets: 20, 30 or 50 pcs. |
Dosage Form, Packaging, and Composition
Coated tablets white, round, biconvex.
| 1 tab. | |
| Salicylamide (calculated on dry substance) | 35 mg |
| Dry extract of Rubia tinctorum (with a content of total anthraglycosides calculated as ruberythric acid and absolutely dry substance 8%) | 32.5 mg |
| Dry extract of Canadian goldenrod (with a content of total flavonoids calculated as rutin and absolutely dry substance 12%) | 25 mg |
| Dry extract of Equisetum arvense (with a content of total flavonoids calculated as rutin and absolutely dry substance 1%) | 15 mg |
| Khellin (calculated on dry substance) | 2.5 mg |
| Convallaria glycoside (with a content of total cardiac glycosides calculated as convallatoxin 30%) | 0.125 mg |
Excipients: potato starch – 44.625 mg, magnesium dihydrogen phosphate (monobasic magnesium phosphate) tetrahydrate – 10 mg, Aerosil (colloidal silicon dioxide) – 8.75 mg, calcium stearate – 1.5 mg.
Shell excipients: sugar (sucrose) – 92.388 mg, basic magnesium carbonate (magnesium hydroxycarbonate) – 26.255 mg, titanium dioxide – 3.76 mg, Aerosil (colloidal silicon dioxide) – 1.642 mg, low molecular weight medical polyvinylpyrrolidone (povidone) – 0.835 mg, beeswax – 0.065 mg, vaseline oil – 0.055 mg.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
Clinical-Pharmacological Group
Herbal preparation with diuretic, spasmolytic, and anti-inflammatory action
Pharmacotherapeutic Group
Spasmolytic agent of plant origin
Pharmacological Action
A combined preparation. It has a spasmolytic, diuretic, and anti-inflammatory effect.
It promotes the passage of renal calculi consisting of calcium oxalates and phosphates. It relieves and reduces pain in renal colic. It increases diuresis. It acidifies urine with its persistent alkaline reaction.
Indications
Phosphate and oxalate nephrourolithiasis, including cases complicated by calculous pyelonephritis; prevention of relapses after surgical removal of kidney stones or their spontaneous passage; salt diathesis (phosphaturia, oxaluria).
ICD codes
| ICD-10 code | Indication |
| N20 | Calculus of kidney and ureter |
| N21 | Calculus of lower urinary tract |
| ICD-11 code | Indication |
| GB70.Z | Calculus of upper urinary tract, unspecified |
| GB71.Z | Calculus of lower urinary tract, unspecified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Take Marelin tablets orally three times daily.
Administer the tablets after meals to minimize potential gastrointestinal discomfort.
For the treatment of phosphate and oxalate nephrourolithiasis, including cases complicated by calculous pyelonephritis, the typical adult dose is 2-4 tablets per administration.
For the prevention of relapses after surgical removal of kidney stones or their spontaneous passage, the typical adult dose is 2 tablets per administration.
For the management of salt diathesis (phosphaturia, oxaluria), the typical adult dose is 1 tablet per administration.
The exact dosage and duration of therapy are determined by the physician based on the clinical presentation, size and composition of calculi, and individual patient response.
The standard course of treatment typically lasts for 20-30 days.
Repeated courses may be prescribed by a physician after a 1-1.5 month interval.
During therapy, maintain adequate hydration by consuming a sufficient volume of fluid.
Do not exceed the prescribed daily dose.
Discontinue use and consult a physician immediately if severe adverse reactions occur.
Adverse Reactions
Allergic reactions: urticaria, angioneurotic edema.
Nervous system disorders: headache, dizziness.
Hearing organ disorders: hearing loss, tinnitus.
Respiratory system disorders: asthma attacks, bronchospasm.
Cardiovascular system disorders: increased blood pressure, arrhythmias.
Digestive system disorders: NSAID-gastropathy, epigastric pain, dyspepsia (nausea, vomiting, heartburn, diarrhea).
Blood clotting system disorders: decreased blood clotting, bleeding.
Other: impaired liver/kidney function, increased sweating, rash, skin itching.
Contraindications
Hypersensitivity to the components of the drug, hypersensitivity to salicylates (including aspirin triad), erosive and ulcerative lesions of the gastrointestinal tract in the acute phase, bronchial asthma, chronic heart failure, cardiosclerosis, myocardial infarction, angina pectoris, ventricular tachycardia, endocarditis, myocarditis, AV block II-III degree, edema, arterial hypertension, blood clotting disorders, severe renal failure, acute and chronic glomerulonephritis, severe liver dysfunction, hearing loss, vestibular apparatus pathology, simultaneous use of methotrexate at a dose of ≥15 mg/week, sucrase/isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption, age under 18 years.
With caution: concomitant therapy with anticoagulants; gastric and duodenal ulcer (in history); congenital hyperbilirubinemias (Gilbert, Dubin-Johnson and Rotor syndromes); gout; hyperuricemia; renal and/or hepatic insufficiency; COPD, hay fever, nasal polyposis, simultaneous use of methotrexate at a dose of less than 15 mg/week.
Use in Hepatic Impairment
With caution hepatic insufficiency.
Use in Renal Impairment
With caution renal insufficiency.
Use is contraindicated in severe renal impairment.
Special Precautions
The preparation contains lily of the valley glycoside, which should be taken into account by patients taking cardiac glycosides.
Influence on the ability to drive vehicles and mechanisms
Caution should be exercised when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions when using the drug.
Drug Interactions
Salicylamide enhances the effect of indirect anticoagulants, antiplatelet agents, fibrinolytics, as well as the side effects of mineralo- and glucocorticoids, estrogens, hepatotoxic and nephrotoxic drugs.
It reduces the effectiveness of antihypertensive drugs, diuretics, uricosuric drugs.
Inducers of microsomal oxidation in the liver (including phenytoin, ethanol, barbiturates, rifampicin, phenylbutazone, tricyclic antidepressants) increase the metabolism of salicylamide.
When used simultaneously with ethanol, the risk of acute pancreatitis increases.
Antacids and cholestyramine reduce the absorption of salicylamide.
Myelotoxic drugs enhance the manifestations of hematotoxicity of salicylamide.
During treatment with salicylamide, the side effects of methotrexate are enhanced.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer